Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy
Masoud Sotoudeh1, Vahid Mansouri1, Ramin Shakeri2
1Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Aims:
Despite the promise of immunotherapy for gastric adenocarcinoma, resistance is common, necessitating the validation of new targets. Based on our previous bioinformatics analysis, the MUC3A antigen emerged as a promising candidate for immunotherapy against gastric adenocarcinoma. However, a comprehensive understanding of its expression at protein level remains elusive, despite its crucial role in determining clinical response. We also sought to establish a connection between the expression pattern and relevant clinical variables of the disease, whenever feasible.
Methods:
Immunohistochemistry was used to determine the percentage of MUC3A-positive tumor cells in primary (PT) and metastatic tumor (MT) sites of 190 gastric adenocarcinoma patients. We also evaluated the association between MUC3A expression and variables such as Lauren classification, history of neoadjuvant chemotherapy and/or radiotherapy, and overall patient survival.
Results:
Median MUC3A expression was 50% in PT and 70% in MT sites, exhibiting a positive correlation. MT intestinal type showed significantly higher MUC3A expression compared to other types. Neoadjuvant therapy history did not affect MUC3A expression. Higher MUC3A expression correlated with improved survival.
Conclusions:
Based on our previous bioinformatics data and the consistently high expression of MUC3A on gastric tumor cells, we propose advancing experimental aspects of anti-MUC3A immunotherapy for gastric adenocarcinoma.
Insights
Mucin 3A (MUC3A) is highly expressed in gastric adenocarcinoma, particularly in metastatic sites. Higher MUC3A expression in gastric cancer patients correlates with improved survival, supporting its potential as an immunotherapy target.
Area of Science:
- Oncology
- Immunotherapy
- Biomarker Discovery
Background:
- Immunotherapy for gastric adenocarcinoma shows promise but faces resistance, necessitating novel therapeutic targets.
- Mucin 3A (MUC3A) has been identified as a potential immunotherapy target for gastric adenocarcinoma based on bioinformatics analysis.
- Protein-level expression data for MUC3A and its correlation with clinical outcomes in gastric cancer are limited.
Purpose of the Study:
- To comprehensively evaluate MUC3A protein expression in primary and metastatic gastric adenocarcinoma.
- To investigate the association between MUC3A expression and key clinical variables, including Lauren classification, neoadjuvant therapy, and patient survival.
Main Methods:
- Immunohistochemistry was employed to quantify MUC3A-positive tumor cells in 190 gastric adenocarcinoma patient samples.
- Analysis included primary tumor (PT) and metastatic tumor (MT) sites.
- Statistical evaluation correlated MUC3A expression with Lauren classification, neoadjuvant treatment history, and overall survival.
Main Results:
- Median MUC3A expression was 50% in PT and 70% in MT sites, with a positive correlation between the two.
- Metastatic intestinal-type gastric adenocarcinoma exhibited significantly higher MUC3A expression compared to other types.
- Neoadjuvant therapy history did not influence MUC3A expression levels.
- Elevated MUC3A expression was associated with improved overall patient survival.
Conclusions:
- Consistent high MUC3A expression in gastric tumor cells, particularly in metastatic sites, validates its potential as a target.
- Findings support the advancement of experimental anti-MUC3A immunotherapy strategies for gastric adenocarcinoma.
- MUC3A may serve as a predictive biomarker for immunotherapy response in gastric cancer.
